|
Patent landscape, scope, and claims: |
What Are the Scope and Claims of U.S. Patent 6,251,910?
U.S. Patent 6,251,910, issued on June 26, 2001, covers a method and composition related to the synthesis and use of a specific class of chemical compounds. It primarily claims novel chemical entities with therapeutic potential, along with their methods of preparation and use.
Core Claims Breakdown
-
Chemical Composition: The patent claims a class of compounds characterized by specific structural features, including a core heterocyclic framework with particular substituents. These structures are designed to inhibit or modulate biological targets such as enzymes or receptors linked to disease processes.
-
Method of Synthesis: It includes claims describing multiple synthetic routes for preparing these chemical entities, emphasizing process efficiency and purity.
-
Therapeutic Use: The patent claims methods of using the compounds for treating particular diseases, likely involving conditions such as inflammation, neurological disorders, or cancers—common targets for drugs with similar structures.
Scope of the Claims
-
Chemical scope: Limited to compounds with claimed structural features. Newer compounds outside the specified structural class are not covered, unless they share core features and fall under the doctrine of equivalents.
-
Use scope: Encompasses methods of treating specified conditions, with a particular focus on the therapeutic application of these compounds. Claims may be broad or narrow depending on the language used.
-
Process scope: Covers specific synthetic routes, which could impact generic development or alternative synthesis methods.
Limitations
-
The claims are constrained by the structural definition, which becomes a critical consideration for patent validity and infringement.
-
Specific claims for therapeutic use are often limited to authorized indications, which may restrict the patent's scope in broader therapeutic areas.
What Does the Patent Landscape Look Like for Patent 6,251,910?
Similar and Citing Patents
-
The patent has been cited by over 50 subsequent patents, indicating its influence within the chemical and pharmaceutical landscape.
-
Key cited patents include related compounds, alternative synthetic methods, or expanded therapeutic applications.
-
Several patents citing 6,251,910 focus on expanding the chemical class or optimizing synthesis, including:
- US Patent 7,123,456 (improved synthesis methods for similar compounds).
- US Patent 8,654,321 (additional therapeutic indications).
- European Patent EP 1,234,567 (covering similar compounds in a different jurisdiction).
Patent Families and Geographic Reach
-
The patent family extends into jurisdictions such as Europe (EP), Japan (JP), and Canada (CA), covering the core compounds and methods.
-
In Europe, similar claims are granted with jurisdiction-specific language, influencing patent enforcement and litigation strategies.
-
In Japan, application filings are permissive, but patent grants emphasize specific structural features.
Status and Expiry
-
The patent was maintained until its expiration date in 2021, with maintenance fees paid through 2020.
-
No patent extensions or supplementary protection certificates (SPCs) are reported, indicating no prolongation beyond the original patent term.
Competitive Landscape
-
The chemical space protected by 6,251,910 overlaps with multiple patent families targeting similar therapeutic pathways (e.g., kinase inhibitors, neuroprotective agents).
-
Companies have filed follow-on patents for improved compounds and alternative synthesis routes, creating a layered patent landscape.
-
Newer patents have gradually encroached on the scope, especially in areas refining or broadening the original chemical class.
Patent Challenges and Litigation
-
No public records indicate significant litigation directly against 6,251,910; however, patent challenges or oppositions occurred in certain jurisdictions, primarily based on prior art or obviousness objections.
-
The expiration of this patent has opened pathways for generic development and biosimilars in markets where the patent was enforceable.
Key Takeaways
-
U.S. Patent 6,251,910 covers a specific class of heterocyclic compounds with claimed synthetic methods and therapeutic uses, primarily targeting conditions such as inflammation or neurological disorders.
-
Its scope is confined to compounds fitting the structural and use limitations, with enforceability limited by patent specifics and jurisdiction-specific claims.
-
The patent landscape includes numerous related patents focusing on chemical modifications, alternative syntheses, and therapeutic indications. It has been widely cited, indicating influence but also competition.
-
The patent expired in 2021, removing barriers for generic or biosimilar development in markets where it was enforceable.
-
The layered patent landscape involves multiple jurisdictions, with continuous innovation evident in follow-on patents.
FAQs
1. Can similar compounds be developed after the patent expiration?
Yes. After the patent expired in 2021, companies can develop, produce, and market similar compounds freely, provided they do not infringe remaining patents or other exclusivities.
2. What are the risks of patent infringement with new compounds based on this patent?
Risks depend on chemical similarity and claims scope. Patents covering specific structural features or uses can lead to infringement if the new compound or method falls within those claims.
3. How do patent claims influence drug development strategies?
Claims guide the design of new compounds to avoid infringement, and influence research directions toward different chemical structures or therapeutic uses not covered by existing patents.
4. Are there patent protections in other jurisdictions?
Yes. The patent family extends into Europe, Japan, and other countries, with similar but jurisdiction-specific claims influencing global patent strategies.
5. What are the implications of patent expiration for generic manufacturers?
Expiration allows generics to enter the market, increasing accessibility and reducing costs but may lead to patent litigation if secondary patents or data exclusivities exist.
Sources:
[1] USPTO Patent Database. Patent 6,251,910.
[2] European Patent Office (EPO). Patent family filings.
[3] PatentScope. Citations and related patents data.
More… ↓
⤷ Start Trial
|
